SOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector, will present a company overview at the J.P. Morgan 38th Annual Healthcare Conference on Wednesday, January 15, 2020 at 4:30 p.m. PT. The conference is being held January 12-16, 2020 in San Francisco.
A live webcast of the presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event. For further information, please contact email@example.com.
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Dan Budwick, 973-271-6085
Source: Alector, Inc.